

11<sup>th</sup> February 2026  
IOLCP/GGC/2026

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051  
**Security Symbol: IOLCP**

**BSE Limited,**  
Pheroze Jeejeebhoy Tower,  
Dalal Street, Mumbai- 400 001  
**Security Code: 524164**

**Subject: Outcome of the Board Meeting and submission of Un-Audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December 2025**

Dear Sir,

Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held on today i.e. 11<sup>th</sup> February 2026 has inter alia considered and approved:

1. Standalone & Consolidated Un-Audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December 2025. The copy of the said Financial Results alongwith Limited Review Report of Statutory Auditors is enclosed herewith as "**Annexure – 1**".
2. Declared an Interim Dividend of Rs. 1/- (50%) per Equity Share of Face Value Rs.2/- each for the Financial Year 2025-26 and fixed **17<sup>th</sup> February 2026** as the **Record Date** to determine the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders within 30 days of declaration.

We confirm and declare that the Limited Review Report issued by the Statutory Auditors on the financial results for the quarter and nine months ended 31<sup>st</sup> December 2025 is an Unmodified Report.

The meeting of the Board of Directors commenced at 1:15 PM and concluded at 2:31 PM.

The above Un-Audited Financial Results are also available on the website of the Company i.e. [www.iolcp.com](http://www.iolcp.com).

This is for your information & record.

Thanking You,

Yours faithfully,  
for IOL Chemicals and Pharmaceuticals Limited



Abhay Raj Singh  
Sr. Vice President & Company Secretary



**Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
IOL Chemicals and Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s IOL Chemicals and Pharmaceuticals Limited** (the "Company") for the quarter and nine months period ended 31<sup>st</sup> December ,2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other



accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Ashwani & Associates**  
**Chartered Accountants**  
**Firm Registration No.: 000497N**  
**by the hand of**



**Arvind Jain**  
**Partner**  
**M. No.: 097549**  
**UDIN: 26097549F0NWLZ1458**

**Place: Ludhiana**  
**Dated: 11.02.2026**



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS PERIOD ENDED 31-DECEMBER-2025

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2025 (Unaudited)	30-Sep-2025 (Unaudited)	31-Dec-2024 (Unaudited)	31-Dec-2025 (Unaudited)	31-Dec-2024 (Unaudited)	31-Mar-2025 (Audited)
	<b>Income:</b>						
I	Revenue from operations	580.39	567.53	523.30	1,699.61	1,551.43	2,079.21
II	Other Income	5.29	6.88	4.07	19.54	17.88	22.40
III	<b>Total income (I+II)</b>	<b>585.68</b>	<b>574.41</b>	<b>527.37</b>	<b>1,719.15</b>	<b>1,569.31</b>	<b>2,101.61</b>
	<b>Expenses:</b>						
IV	Cost of materials consumed	356.70	366.70	335.96	1,099.95	1,010.73	1,358.34
	Purchases of stock-in-trade	0.19	-	-	0.19	-	-
	Changes in inventories of finished goods, work-in-progress and stock in trade	25.55	1.47	18.09	14.70	35.33	33.51
	Employee benefits expense	56.93	63.35	52.43	177.93	164.18	216.57
	Finance costs	3.63	3.48	4.46	11.34	10.73	14.76
	Depreciation and amortization expenses	20.17	19.98	18.66	59.90	53.39	71.92
	Other expenses	83.75	78.91	69.95	230.32	201.96	268.62
	<b>Total Expenses (IV)</b>	<b>546.92</b>	<b>533.89</b>	<b>499.55</b>	<b>1,594.33</b>	<b>1,476.32</b>	<b>1,963.72</b>
V	Profit before exceptional items and tax (III-IV)	38.76	40.52	27.82	124.82	92.99	137.89
VI	Exceptional items	11.21	-	-	11.21	-	-
VII	Profit before tax (V-VI)	27.55	40.52	27.82	113.61	92.99	137.89
VIII	<b>Tax Expense:</b>						
	Current tax	5.98	8.96	4.34	25.43	17.68	24.74
	Deferred tax	0.99	1.56	2.93	3.64	5.93	12.15
	<b>Total tax expense</b>	<b>6.97</b>	<b>10.52</b>	<b>7.27</b>	<b>29.07</b>	<b>23.61</b>	<b>36.89</b>
IX	Profit for the period (VII-VIII)	20.58	30.00	20.55	84.54	69.38	101.00
X	<b>Other Comprehensive Income</b>						
A (i)	Items that will not be reclassified to profit or loss	1.08	0.72	(0.06)	(0.10)	(1.91)	(0.97)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	(0.27)	(0.18)	0.01	0.03	0.48	0.24
B (i)	Items that will be reclassified to profit or loss	(0.89)	(0.20)	(0.09)	(0.05)	(0.04)	(0.95)
(ii)	Income tax relating to items that will be reclassified to profit or loss	0.22	0.05	0.03	0.01	0.01	0.24
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>20.72</b>	<b>30.39</b>	<b>20.44</b>	<b>84.43</b>	<b>67.92</b>	<b>99.56</b>
XII	Paid-up equity share capital (Face value ₹2/- per share)	58.71	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,713.13	1,692.41	1,620.54	1,713.13	1,620.54	1,628.70
XIV	Earning per equity share of ₹2/- each (for continuing and discontinued operations) (not annualised except for the year ended 31-Mar-2025) Basic and Diluted ₹	0.70	1.02	0.70	2.88	2.36	3.44



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91- 161-2225531-35 Fax : +91 - 161-2226929, email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : 91-1679 - 285285-86

**STANDALONE SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES**

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2025	30-Sep-2025	31-Dec-2024	31-Dec-2025	31-Dec-2024	31-Mar-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Segment Revenue</b>						
	(Net sale/income)						
	- Chemical	287.82	285.23	275.14	854.11	818.15	1,079.39
	- Pharmaceutical	356.05	336.36	300.58	1,021.74	890.05	1,212.32
	- Unallocated	5.30	6.87	4.07	19.54	17.88	22.42
	<b>Total</b>	<b>649.17</b>	<b>628.46</b>	<b>579.79</b>	<b>1,895.39</b>	<b>1,726.08</b>	<b>2,314.13</b>
	Less : Inter segment revenue	63.49	54.05	52.42	176.24	156.77	212.52
<b>Net sales/income from operations</b>	<b>585.68</b>	<b>574.41</b>	<b>527.37</b>	<b>1,719.15</b>	<b>1,569.31</b>	<b>2,101.61</b>	
2	<b>Segment Results</b>						
	Profit before tax and interest						
	(from each segment)						
	- Chemical	6.46	5.05	4.72	17.42	8.87	15.39
	- Pharmaceutical	34.50	35.45	26.14	110.04	85.35	126.27
	<b>Total</b>	<b>40.96</b>	<b>40.50</b>	<b>30.86</b>	<b>127.46</b>	<b>94.22</b>	<b>141.66</b>
	Less: Interest	3.63	3.48	4.46	11.34	10.73	14.76
Add: Other un-allocable income net off un-allocable expenditure	1.43	3.50	1.42	8.70	9.50	10.99	
<b>Total Profit before tax &amp; Extraordinary items</b>	<b>38.76</b>	<b>40.52</b>	<b>27.82</b>	<b>124.82</b>	<b>92.99</b>	<b>137.89</b>	
3	<b>Segment Assets</b>						
	- Chemical	544.83	550.67	531.33	544.83	531.33	534.85
	- Pharmaceutical	1,455.44	1,415.96	1,317.03	1,455.44	1,317.03	1,381.71
	- Unallocated	437.95	446.23	457.11	437.95	457.11	465.22
	<b>Total Assets</b>	<b>2,438.22</b>	<b>2,412.86</b>	<b>2,305.47</b>	<b>2,438.22</b>	<b>2,305.47</b>	<b>2,381.78</b>
4	<b>Segment Liabilities</b>						
	- Chemical	235.23	202.44	219.44	235.23	219.44	300.16
	- Pharmaceutical	181.09	191.98	180.72	181.09	180.72	194.88
	- Unallocated	250.06	267.32	226.06	250.06	226.06	199.33
	<b>Total Liabilities</b>	<b>666.38</b>	<b>661.74</b>	<b>626.22</b>	<b>666.38</b>	<b>626.22</b>	<b>694.37</b>



**Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
IOL Chemicals and Pharmaceuticals Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s IOL Chemicals and Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months period ended 31<sup>st</sup> December, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the Parent and the following entities:

**Subsidiary Companies**

- i. M/s IOL Specialty Chemicals Limited
- ii. M/s IOL Life Sciences Limited\*
- iii. M/s IOL Foundation
- iv. M/s IOL Pharmaxis UK Limited\*\*

\*Application for striking off has been filed with the Registrar of Companies (“ROC”), Ministry of Corporate Affairs on 27 January 2026.

\*\*The business operations of the company have not yet commenced.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Ashwani & Associates**

**Chartered Accountants**

**Firm Registration No.: 000497N**

by the hand of



**Arvind Jain**

**Partner**

**M. No.:097549**

**UDIN: 26097549 BBRZ x13955**

**Place: Ludhiana**

**Dated:11.02.2026**

**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS PERIOD ENDED 31-DECEMBER-2025**

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2025	30-Sep-2025	31-Dec-2024	31-Dec-2025	31-Dec-2024	31-Mar-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	<b>Income:</b>						
I	Revenue from operations	580.39	567.53	523.30	1,699.61	1,551.43	2,079.21
II	Other Income	5.29	6.88	4.07	19.54	17.88	22.41
III	<b>Total income (I+II)</b>	<b>585.68</b>	<b>574.41</b>	<b>527.37</b>	<b>1,719.15</b>	<b>1,569.31</b>	<b>2,101.62</b>
	<b>Expenses:</b>						
	Cost of materials consumed	356.70	366.70	335.96	1,099.95	1,010.73	1,358.34
	Purchases of stock-in-trade	0.19	-	-	0.19	-	-
	Changes in inventories of finished goods, work-in-progress and stock in trade	25.55	1.47	18.09	14.70	35.33	33.51
	Employee benefits expense	56.93	63.35	52.43	177.93	164.18	216.57
	Finance costs	3.63	3.48	4.46	11.34	10.73	14.76
	Depreciation and amortization expenses	20.18	19.99	18.68	59.94	53.44	71.99
	Other expenses	83.74	78.93	69.95	230.34	201.64	268.49
	<b>Total Expenses (IV)</b>	<b>546.92</b>	<b>533.92</b>	<b>499.57</b>	<b>1,594.39</b>	<b>1,476.05</b>	<b>1,963.66</b>
V	Profit before exceptional items and tax (III-IV)	38.76	40.49	27.80	124.76	93.26	137.96
VI	Exceptional items	11.21	-	-	11.21	-	-
VII	Profit before tax (V-VI)	27.55	40.49	27.80	113.55	93.26	137.96
VIII	<b>Tax Expense:</b>						
	Current tax	5.98	8.96	4.34	25.43	17.68	24.74
	Deferred tax	0.99	1.56	2.93	3.64	5.93	12.15
	<b>Total tax expense</b>	<b>6.97</b>	<b>10.52</b>	<b>7.27</b>	<b>29.07</b>	<b>23.61</b>	<b>36.89</b>
IX	<b>Profit for the period (VII-VIII)</b>	<b>20.58</b>	<b>29.97</b>	<b>20.53</b>	<b>84.48</b>	<b>69.65</b>	<b>101.07</b>
X	<b>Other Comprehensive Income</b>						
A (i)	Items that will not be reclassified to profit or loss	1.08	0.72	(0.06)	(0.10)	(1.91)	(0.97)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	(0.27)	(0.18)	0.01	0.03	0.48	0.24
B (i)	Items that will be reclassified to profit or loss	(0.89)	(0.20)	(0.09)	(0.05)	(0.04)	(0.95)
(ii)	Income tax relating to items that will be reclassified to profit or loss	0.22	0.05	0.03	0.01	0.01	0.24
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>20.72</b>	<b>30.36</b>	<b>20.42</b>	<b>84.37</b>	<b>68.19</b>	<b>99.63</b>
XII	Paid-up equity share capital (Face value ₹2/- per share)	58.71	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,713.32	1,692.60	1,620.99	1,713.32	1,620.99	1,628.95
XIV	Earning per equity share of ₹2/- each (for continuing and discontinued operations) (not annualised except for the year ended 31-Mar-2025)						
	Basic and Diluted ₹	0.70	1.02	0.70	2.88	2.37	3.44



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91- 161-2225531-35 Fax : +91 - 161-2226929, email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : 91-1679 - 285285-86



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2025 (Unaudited)	30-Sep-2025 (Unaudited)	31-Dec-2024 (Unaudited)	31-Dec-2025 (Unaudited)	31-Dec-2024 (Unaudited)	31-Mar-2025 (Audited)
1	<b>Segment Revenue</b>						
	(Net sale/income)						
	- Chemical	287.82	285.23	275.14	854.11	818.15	1,079.39
	- Pharmaceutical	356.05	336.36	300.58	1,021.74	890.05	1,212.32
	- Unallocated	5.30	6.87	4.07	19.54	17.88	22.43
	<b>Total</b>	<b>649.17</b>	<b>628.46</b>	<b>579.79</b>	<b>1,895.39</b>	<b>1,726.08</b>	<b>2,314.14</b>
	Less : Inter segment revenue	63.49	54.05	52.42	176.24	156.77	212.52
	<b>Net sales/income from operations</b>	<b>585.68</b>	<b>574.41</b>	<b>527.37</b>	<b>1,719.15</b>	<b>1,569.31</b>	<b>2,101.62</b>
2	<b>Segment Results</b>						
	Profit before tax and interest (from each segment)						
	- Chemical	6.46	5.05	4.72	17.42	8.87	15.39
	- Pharmaceutical	34.50	35.45	26.14	110.04	85.35	126.27
	<b>Total</b>	<b>40.96</b>	<b>40.50</b>	<b>30.86</b>	<b>127.46</b>	<b>94.22</b>	<b>141.66</b>
	Less: Interest	3.63	3.48	4.46	11.34	10.73	14.76
	Add: Other un-allocable income net off un-allocable expenditure	1.43	3.47	1.40	8.64	9.77	11.06
	<b>Total Profit before tax &amp; Extraordinary items</b>	<b>38.76</b>	<b>40.49</b>	<b>27.80</b>	<b>124.76</b>	<b>93.26</b>	<b>137.96</b>
3	<b>Segment Assets</b>						
	- Chemical	544.83	550.67	531.33	544.83	531.33	534.85
	- Pharmaceutical	1,455.44	1,415.96	1,317.03	1,455.44	1,317.03	1,381.71
	- Unallocated	438.24	446.46	457.59	438.24	457.59	465.51
	<b>Total Assets</b>	<b>2,438.51</b>	<b>2,413.09</b>	<b>2,305.95</b>	<b>2,438.51</b>	<b>2,305.95</b>	<b>2,382.07</b>
4	<b>Segment Liabilities</b>						
	- Chemical	235.23	202.44	219.44	235.23	219.44	300.16
	- Pharmaceutical	181.09	191.98	180.72	181.09	180.72	194.88
	- Unallocated	250.16	267.36	226.09	250.16	226.09	199.37
	<b>Total Liabilities</b>	<b>666.48</b>	<b>661.78</b>	<b>626.25</b>	<b>666.48</b>	<b>626.25</b>	<b>694.41</b>




Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91- 161-2225531-35 Fax : +91 - 161-2226929, email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : 91-1679 - 285285-86



**NOTES:**

1. The aforesaid standalone and consolidated unaudited financial results for the quarter and nine months ended 31<sup>st</sup> December 2025 were reviewed and recommended by the Audit Committee to the Board of Directors and subsequently approved by the Board of Directors at their respective meetings held on 11<sup>th</sup> February 2026. The said financial results have been subjected to a Limited Review by the Statutory Auditors of the Company, who have issued an unmodified report thereon. The financial results, along with the Auditor's Report, are being filed with the National Stock Exchange of India Limited and BSE Limited and are also available on the Company's website.
2. The financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Government of India, on 21<sup>st</sup> November 2025, notified the four Labour Codes—namely the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating the existing labour laws. The Company has assessed the incremental impact based on the best information available as at the reporting date. Given the regulatory-driven and non-recurring nature, the impact of Rs. 11.21 crore, primarily arising from changes in the wage definition, has been disclosed as an Exceptional Item in the financial results for the period ended 31<sup>st</sup> December 2025. The Company continues to monitor developments on the rules including clarifications/ additional guidance from authorities and will continue to assess the accounting implications basis such developments/ guidance as needed.
4. The Board of Directors has declared an Interim Dividend of Rs 1/- (50 %) per Equity Share having face value of Rs 2/- each, for the financial year 2025- 26. The Record Date for the purpose of ascertaining the entitlement of receiving the interim dividend has been fixed on 17<sup>th</sup> February 2026.
5. During the quarter ended 31<sup>st</sup> December 2025, the Board of Directors approved the closure of *IOL Life Sciences Limited*, a wholly owned subsidiary of the Company, by way of striking off its name from the Register of Companies in accordance with Section 248 of the Companies Act, 2013. Pursuant to the said approval, an application for striking off was filed with the Registrar of Companies ("RoC"), Ministry of Corporate Affairs, on 27<sup>th</sup> January 2026.
6. During the quarter ended 31<sup>st</sup> December 2025, the Company incorporated an overseas wholly owned subsidiary, *IOL Pharmaxis UK Limited*, in the United Kingdom on 16<sup>th</sup> October 2025 under the Companies Act, 2006 of England and Wales, and the business operations have not yet commenced.



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030

Ph. : +91- 161-2225531-35 Fax : +91 - 161-2226929, email : contact@iolcp.com Website : iolcp.com

Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.

Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.

Ph. : 91-1679 - 285285-86

7. In accordance with Ind AS 108 – *Operating Segments*, the Company has identified two reportable operating segments, namely ‘Pharmaceuticals’ and ‘Chemicals’. The financial information relating to these operating segments is disclosed in the Financial Results.
8. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary.

by order of the Board  
IOL Chemicals and Pharmaceuticals Limited



Vikas Gupta  
Joint Managing Director  
DIN: 07198109

Place: Ludhiana  
Date: 11<sup>th</sup> February 2026